License and Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Year Ended December 31,
Partner	Agreement	2021		2020		2019
Bristol-Myers Squibb	Bempegaldesleukin	$	—	$	50,000	$	—
Eli Lilly and Company	NKTR-358	—		1,259		7,019
Amgen, Inc.	Neulasta®	—		4,167		5,000
Other		436		423		4,956
License, collaboration and other revenue		$	436	$	55,849	$	16,975